Shares of Hims & Hers Health fell nearly 18% on Tuesday, November 10, after the telehealth company reported its third-quarter results and issued a weaker-than-expected revenue forecast for the final quarter of 2026.
The stock declined as much as 19% during the trading session, reflecting investor concerns over the company's outlook, declining gross margins and slower subscriber growth.
Hims & Hers reported third-quarter revenue of $890.4 million, representing a 49% increase from the same period last year. The figure was broadly in line with analyst expectations, according to Bloomberg data. However, gross margin fell to 57% from 74% a year earlier, while subscriber growth also came in below expectations.
The company's fourth-quarter revenue forecast added to the pressure. Hims & Hers expects revenue between $875 million and $895 million, below the $955.1 million analysts had anticipated. The outlook raised concerns about the company's ability to maintain growth while managing profitability.
The stock has also faced pressure from regulatory and legal challenges involving its compounded GLP-1 weight-loss medications. The company has since shifted away from copycat weight-loss drugs and pursued partnerships with pharmaceutical manufacturers.
In another setback, the Federal Trade Commission filed a lawsuit against Hims & Hers in late July, alleging that the company shared private health information with advertisers Meta and Snap and made subscription cancellations difficult. The company has rejected the allegations and said it would fight the case.
Hims & Hers shares are down approximately 38% so far in 2026, reflecting a difficult year for the telehealth business.


0 comments
No comments yet. Yours would be the first.